Table 1 Reports in the literature of immunotherapy-associated renal adverse events and treatment
From: Nivolumab-associated acute glomerulonephritis: a case report and literature review
Author | No. of patients | Age | Gender | Medication | Cancer | Kidney biopsy | Treatment | Outcome |
|---|---|---|---|---|---|---|---|---|
Fadel et al. [11] 2009 | 1 | 64 | M | Ipilimumab | Melanoma | Extra-membranous and mesangial deposits of immunoglobulin (consistent with lupus nephritis) | Steroids | Resolved |
Forde et al. [12] 2012 | 1 | 59 | M | Ipilimumab | Melanoma | Not available | Steroids; no dialysis | Resolved |
Voskens et al. [13] 2013 | 1 | 53 | F | Ipilimumab | Mucosal | Not available | Steroids | Resolved |
2 | 72 | F | Ipilimumab | Unknown primary | Not available | Steroids | Resolved | |
Izzedine et al. [14] 2014 | 1 | 72 | M | Ipilimumab | Melanoma | Interstitial inflammation and poly-nuclear infiltration in glomerulus | Steroids | Resolved |
2 | 60 | F | Ipilimumab | Melanoma | Tubulointerstitial inflammation with necrosis and two non-necrotizing granulomas | Steroids | Resolved | |
Thajudeen et al. [15] 2015 | 1 | 74 | M | Ipilimumab | Melanoma | Interstitial edema with infiltrate of lymphocytes and granulomas | Steroids | Resolved; ipilimumab resumed |
Vandiver et al. [16] 2016 | 1 | 58 | F | Nivolumab | Melanoma | Not available | Steroids | Resolved |
Hofmann et al. [17] 2016 | 1 | 52 | M | Nivolumab | Melanoma | Not available | Steroids and normal saline | Resolved; nivolumab resumed |
2 | 73 | M | Pembrolizumab | Melanoma | Not available | Steroids | Improved |